Steven Cohen Ultragenyx Pharmaceutical Inc. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 653,660 shares of RARE stock, worth $30.3 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
653,660
Previous 539,749
21.1%
Holding current value
$30.3 Million
Previous $22.2 Million
63.68%
% of portfolio
0.1%
Previous 0.06%
Shares
27 transactions
Others Institutions Holding RARE
# of Institutions
325Shares Held
85.7MCall Options Held
520KPut Options Held
406K-
Vanguard Group Inc Valley Forge, PA9.95MShares$461 Million0.01% of portfolio
-
Black Rock Inc. New York, NY5.6MShares$260 Million0.01% of portfolio
-
Sands Capital Management, LLC Arlington, VA5.12MShares$237 Million0.91% of portfolio
-
Wellington Management Group LLP Boston, MA4.17MShares$193 Million0.04% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.07MShares$142 Million0.02% of portfolio
About Ultragenyx Pharmaceutical Inc.
- Ticker RARE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,036,896
- Market Cap $3.25B
- Description
- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...